Trials Sponsors Conditions Drugs Pricing

Conditions

Hepatocellular Carcinoma Solid Tumor, Adult

Keywords

Hepatocellular Carcinoma;Lung CancerTrametinibEverolimusLenvatinib

Outcome Measures

Primary Outcomes (1)

Assessing Incidence of Treatment-Emergent Adverse Events during the treatment and various responses to the treatment.
up to 36 months

Secondary Outcomes (2)

Assessing progress free survival
48 months
Assessing overall survival
48 months

Study Arms (1)

Combination treatment of 3 inhibitors

EXPERIMENTAL

Oral administration of 3 signaling pathways inhibitors: Mek inhibitor Trametinib, mTOR inhibitor Everolimus, and angiogenesis inhibitor Lenvatinib on refractory advanced solid tumors.

Drug: Combination of three inhibitors Trametinib, Everolimus and Lenvatinib

Interventions

Combination of three inhibitors Trametinib, Everolimus and LenvatinibDrug

Oral administration of three inhibitors including Trametinib, Everolimus and Lenvatinib.

Also known as: Combination of 3 signaling pathway inhibitors specific to MEK, mTOR, and angiogenesis.

Combination treatment of 3 inhibitors

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Registry intervention entries

These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.

Grouped treatment entry
Combination of three inhibitors Trametinib, Everolimus and Lenvatinib
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry record

Eligibility Criteria

Age18 Years - 85 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Recurrent/Refractory advanced solid tumors
Age between 18 and 85 years

Sponsors & Collaborators

Second Affiliated Hospital of Guangzhou Medical University
Otherlead

Study Sites (1)

The Second Affiliated Hospital of Guangzhou Medical University

Guangzhou, Guangdong, 510260, China

RECRUITING

Zhenfeng Zhang, MD,PhDCONTACT+86-020-39195966 zhangzhf@gzhmu.edu.cn

Bingjia He, MDCONTACT+86-14748877800 464677938@qq.com

MeSH Terms

Conditions

Carcinoma, Hepatocellular

Interventions

EverolimuslenvatinibAngiogenesis

Condition Hierarchy (Ancestors)

AdenocarcinomaCarcinomaNeoplasms, Glandular and EpithelialNeoplasms by Histologic TypeNeoplasmsLiver NeoplasmsDigestive System NeoplasmsNeoplasms by SiteDigestive System DiseasesLiver Diseases

Study Officials

Zhenfeng Zhang, MD, PhD
Second Affiliated Hospital of Guangzhou Medical University
PRINCIPAL INVESTIGATOR

Central Study Contacts

Zhenfeng Zhang, MD, PhD

CONTACT

+862039195966 zhangzhf@gzhmu.edu.cn

Bingjia He, MD

CONTACT

+862039195966

Study Design

Study Type: interventional
Phase: phase 2
Allocation: NA
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

March 15, 2021

First Posted

March 17, 2021

Study Start

January 1, 2021

Actual (reported)

Primary Completion

Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Study Arms (1)

Combination treatment of 3 inhibitors

Interventions

Registry intervention entries

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (2)

Study Arms (1)

Combination treatment of 3 inhibitors

Interventions

Registry intervention entries

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Intervention Hierarchy (Ancestors)

Source record

Locations